You are viewing the site in preview mode

Skip to main content
Fig. 2 | BMC Immunology

Fig. 2

From: Soluble cytotoxic T-lymphocyte–associated antigen 4 (sCTLA-4) as a potential biomarker for diagnosis and evaluation of the prognosis in Glioma

Fig. 2

Serum sCTLA-4 levels in patients with glioma and in controls. Patients with glioma have a statistically higher concentration of circulating sCTLA4 than control subjects (p < 0.05). Median level of sCTLA-4 for the patients with high-grade glioma was higher than those in the low-grade glioma group and control subjects (all p < 0.05). sCTLA-4, soluble cytotoxic T-lymphocyte antigen 4

Back to article page

BMC Immunology

ISSN: 1471-2172

Contact us